Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic lupus erythematosus

B H Hahn1

  • 1Division of Rheumatology, University of California Los Angeles, USA.

The Journal of the Florida Medical Association
|May 1, 1995
PubMed
Summary
This summary is machine-generated.

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with varied symptoms and severity. Treatment for SLE requires individualization based on patient presentation and affected organ systems.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Attraction of mosquitoes to primate odours and implications for zoonotic Plasmodium transmission.

Medical and veterinary entomology·2019
Same author

Oral administration of different forms of a tolerogenic peptide to define the preparations and doses that delay anti-DNA antibody production and nephritis and prolong survival in SLE-prone mice.

Lupus·2011
Same author

Galectin-1-induced down-regulation of T lymphocyte activation protects (NZB x NZW) F1 mice from lupus-like disease.

Lupus·2011
Same author

Interferon-inducible gene 202b controls CD8(+) T cell-mediated suppression in anti-DNA Ig peptide-treated (NZB × NZW) F1 lupus mice.

Genes and immunity·2011
Same author

Pro-inflammatory high-density lipoproteins and atherosclerosis are induced in lupus-prone mice by a high-fat diet and leptin.

Lupus·2010
Same author

Some antiphospholipid antibodies bind to various serine proteases in hemostasis and tip the balance toward hypercoagulant states.

Lupus·2010
Same journal

The dawning of the age of accountability.

The Journal of the Florida Medical Association·1999
Same journal

Physician office-based quality improvement projects. Florida Medical Quality Assurance, Inc.

The Journal of the Florida Medical Association·1998
Same journal

Hyperlipidemia management in patients with cardiovascular and cerebrovascular disease.

The Journal of the Florida Medical Association·1998
Same journal

On the horizon: newly-developed quality improvement projects. Florida Medical Quality Assurance, Inc.

The Journal of the Florida Medical Association·1998
Same journal

Angiotensin converting enzyme inhibitor use in congestive heart failure. Florida Medical Quality Assurance, Inc.

The Journal of the Florida Medical Association·1998
Same journal

Influenza immunization among Medicare beneficiaries enrolled in a health maintenance organization: 1994. Florida Medical Quality Assurance, Inc.

The Journal of the Florida Medical Association·1998
See all related articles

Area of Science:

  • Rheumatology
  • Immunology
  • Genetics

Background:

  • Systemic lupus erythematosus (SLE) is an autoimmune disease with complex genetic and environmental factors.
  • SLE presents with diverse clinical manifestations, often mimicking other conditions.
  • Disease severity and course fluctuate, necessitating personalized treatment strategies.

Purpose of the Study:

  • To summarize the key aspects of systemic lupus erythematosus.
  • To highlight the variable presentation and management challenges of SLE.
  • To outline current therapeutic approaches for SLE patients.

Main Methods:

  • Review of existing literature on SLE pathogenesis and clinical features.
  • Analysis of treatment guidelines and therapeutic outcomes.

Related Experiment Videos

  • Synthesis of information regarding disease management based on patient-specific factors.

    • Main Results:

    • SLE pathogenesis involves both genetic predisposition and environmental triggers.
    • Clinical presentation of SLE is highly variable, affecting multiple organ systems.
    • Treatment approaches range from NSAIDs and antimalarials to high-dose steroids and immunosuppressants like cyclophosphamide.

    Conclusions:

    • Individualized treatment is crucial for managing systemic lupus erythematosus due to its variable nature.
    • Steroids and immunosuppressants are vital for severe SLE manifestations involving critical organs.
    • Effective SLE management requires a tailored approach considering disease activity and organ involvement.